Effect of serum from cardiovascular patients on catalytic activity of secretory phospholipase A2 (IIA).
Incubation of patients' serum catalytically active by type IIA secretory phospholipase A2 (SP-IIA) with serum containing the enzyme in a high concentration but exhibiting no catalytic activity in 1:1 volume ratio led to a significant inhibition of SP-IIA catalytic activity. donor and patient sera with low levels of SP-IIA had no effect on the serum with SP-IIA activity under these conditions. However, the increase in the content of patients' serum with a low level of SP-IIA in the incubation mixture to 1:2 (v/v) and of donor serum to 1:3 (v/v) also led to blockade of SP-IIA catalytic activity. These results indicate that human serum contains an SP-IIA inhibitor and its concentration decreases significantly in sera with SP-IIA activity.
Samoilova
E V
EV
Russian Cardiological Center, Russian Ministry of Health, Moscow. samoilova@cardio.ru
Pirkova
A A
AA
Prokazova
N V
NV
Korotaeva
A A
AA
D000787:Angina Pectoris / Q000097:blood*; D002384:Catalysis; D004791:Enzyme Inhibitors / Q000097:blood; D054501:Group II Phospholipases A2; D006801:Humans; D010741:Phospholipases A / Q000037:antagonists & inhibitors / Q000378:metabolism*; D054467:Phospholipases A2; D013729:Terpenes / Q000494:pharmacology
D004791:Enzyme Inhibitors; D013729:Terpenes; C045673:manoalide; D010741:Phospholipases A; D054501:Group II Phospholipases A2; D054467:Phospholipases A2